| scholarly article | Q13442814 |
| P356 | DOI | 10.1155/2012/739274 |
| P8608 | Fatcat ID | release_s3gkwanmpjfdvnogxhw3dhd4se |
| P932 | PMC publication ID | 3546487 |
| P698 | PubMed publication ID | 23346385 |
| P5875 | ResearchGate publication ID | 235368928 |
| P2093 | author name string | M Rodriguez | |
| J Moreno | |||
| J Hasbun | |||
| P2860 | cites work | Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor | Q24320710 |
| Angiotensin receptors, autoimmunity, and preeclampsia | Q24605647 | ||
| Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth | Q28211595 | ||
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| A reversible posterior leukoencephalopathy syndrome | Q28273132 | ||
| Cerebrovascular function in pregnancy and eclampsia | Q28305037 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features | Q33324816 | ||
| Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia | Q33748650 | ||
| Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity | Q33748680 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Pathogenesis and genetics of pre-eclampsia | Q33934445 | ||
| Plasma from preeclamptic women increases blood-brain barrier permeability: role of vascular endothelial growth factor signaling | Q34222231 | ||
| Latest advances in understanding preeclampsia | Q34425288 | ||
| Acute complications of preeclampsia | Q34669863 | ||
| Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. | Q34702420 | ||
| Clinical spectrum of reversible posterior leukoencephalopathy syndrome | Q34749212 | ||
| Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia | Q34785813 | ||
| Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia | Q35079406 | ||
| Pre-eclampsia, the placenta and the maternal systemic inflammatory response--a review | Q35169648 | ||
| Diagnosis and management of gestational hypertension and preeclampsia | Q35173115 | ||
| Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling | Q35681804 | ||
| Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice | Q35701236 | ||
| Receptor-activating autoantibodies and disease: preeclampsia and beyond | Q35707881 | ||
| Renin angiotensin signaling in normal pregnancy and preeclampsia | Q35743816 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. | Q51359651 | ||
| Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. | Q53468648 | ||
| Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. | Q53600812 | ||
| Placental stress and pre-eclampsia: a revised view. | Q54774592 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q56619493 | ||
| Agonistic Angiotensin II Type 1 Receptor Autoantibodies in Postpartum Women With a History of Preeclampsia | Q56981931 | ||
| Cerebral perfusion pressure, and not cerebral blood flow, may be the critical determinant of intracranial injury in preeclampsia: A new hypothesis | Q59651244 | ||
| Cyclosporine-associated central nervous system toxicity | Q68278231 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Angiotensinogen Thr235 variant is associated with abnormal physiologic change of the uterine spiral arteries in first-trimester decidua | Q77893110 | ||
| Pressor response to angiotonin in pregnant and nonpregnant women | Q78762451 | ||
| [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report] | Q80419671 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| Pre-eclampsia | Q81446389 | ||
| Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia | Q82705098 | ||
| Cerebral hemodynamics and autoregulation in reversible posterior leukoencephalopathy syndrome caused by pre-/eclampsia | Q83968345 | ||
| ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists | Q95804650 | ||
| Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean | Q35834763 | ||
| Enhanced expression of Ang-(1-7) during pregnancy | Q35845564 | ||
| Diagnosis, prevention, and management of eclampsia | Q36026219 | ||
| Developmental biology of the placenta and the origins of placental insufficiency | Q36030154 | ||
| Role of the renin-angiotensin system in the pathogenesis of preeclampsia | Q36064478 | ||
| Circulating angiogenic factors in preeclampsia | Q36086665 | ||
| The role of RAS in the pathogenesis of preeclampsia | Q36467563 | ||
| Endothelial dysfunction in pre-eclampsia. | Q36749162 | ||
| Preeclampsia and angiogenic imbalance | Q36971766 | ||
| The functional role of the renin-angiotensin system in pregnancy and preeclampsia | Q37039872 | ||
| AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia | Q37132801 | ||
| Systemic and uteroplacental renin--angiotensin system in normal and pre-eclamptic pregnancies | Q37218199 | ||
| Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats | Q37436219 | ||
| Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. | Q37447371 | ||
| The global impact of pre-eclampsia and eclampsia | Q37493240 | ||
| Neurologic complications of pre-eclampsia | Q37493270 | ||
| Preeclampsia: the role of angiogenic factors in its pathogenesis | Q37512886 | ||
| Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces | Q37769182 | ||
| ACOG technology assessment. Genetics and molecular diagnostic testing. Number 1, July 2002. American College of Obstetrics and Gynecology | Q40616036 | ||
| Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation | Q40735093 | ||
| A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. | Q40853474 | ||
| Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats | Q42040950 | ||
| Functional analysis of vascular dysfunction in cyclosporin treated rats | Q42492682 | ||
| Effect of angiotensin II synthesis blockade on the hypertensive response to chronic reductions in uterine perfusion pressure in pregnant rats. | Q43744800 | ||
| Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation | Q44218760 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| Late postpartum eclampsia: a preventable disease? | Q44831228 | ||
| Oxidative stress and inflammatory markers in normal pregnancy and preeclampsia | Q46243719 | ||
| Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. | Q46339760 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial | Q46351253 | ||
| Eclampsia. VIII. Risk factors for maternal morbidity | Q46355410 | ||
| Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases | Q46371211 | ||
| Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected | Q46644571 | ||
| Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness | Q46841539 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Impaired dynamic cerebral autoregulation in eclampsia | Q48179564 | ||
| Disturbance of blood-brain barrier after bone-marrow transplantation | Q48462853 | ||
| Magnesium sulfate decreases cerebral perfusion pressure in preeclampsia | Q48464751 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | pre-eclampsia | Q61335 |
| P304 | page(s) | 739274 | |
| P577 | publication date | 2012-12-30 | |
| P1433 | published in | International Journal of Hypertension | Q24031588 |
| P1476 | title | RAS in Pregnancy and Preeclampsia and Eclampsia | |
| P478 | volume | 2012 |
Search more.